Pyxis Oncology - PYXS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.00
  • Forecasted Upside: 135.60%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$3.82
+0 (0.00%)

This chart shows the closing price for PYXS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Pyxis Oncology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PYXS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PYXS

Analyst Price Target is $9.00
▲ +135.60% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Pyxis Oncology in the last 3 months. The average price target is $9.00, with a high forecast of $12.00 and a low forecast of $7.00. The average price target represents a 135.60% upside from the last price of $3.82.

This chart shows the closing price for PYXS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 8 polled investment analysts is to buy stock in Pyxis Oncology. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/9/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/7/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/5/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/3/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/3/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/1/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/30/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/30/2024

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/19/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$7.00 ➝ $7.00
8/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
8/8/2024Stifel NicolausInitiated CoverageBuy$10.00
5/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00
5/7/2024Jefferies Financial GroupReiterated RatingBuy ➝ Buy$10.00
4/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00
3/22/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$7.00
3/22/2024HC WainwrightBoost TargetBuy ➝ Buy$4.00 ➝ $7.00
2/9/2024BTIG ResearchInitiated CoverageBuy$8.00
1/23/2024Leerink PartnrsReiterated RatingOutperform
1/23/2024Leerink PartnersInitiated CoverageOutperform$12.00
11/30/2023HC WainwrightReiterated RatingBuy$4.00
11/8/2023William BlairReiterated RatingOutperform
9/5/2023Royal Bank of CanadaInitiated CoverageOutperform$7.00
4/26/2023Lifesci CapitalReiterated RatingOutperform
3/23/2023Credit Suisse GroupReiterated RatingOutperform$14.00
3/22/2023William BlairReiterated RatingOutperform
12/1/2022Lifesci CapitalReiterated RatingOutperform
11/2/2021Lifesci CapitalReiterated RatingOutperform
11/2/2021William BlairReiterated RatingBuy
11/2/2021Jefferies Financial GroupInitiated CoverageBuy$25.00
11/2/2021Bank of AmericaInitiated CoverageNeutral$16.00
11/2/2021Credit Suisse GroupInitiated CoverageOutperform$19.00
(Data available from 10/30/2019 forward)

News Sentiment Rating

0.86 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/3/2024
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/3/2024
  • 6 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/2/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/2/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/1/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/31/2024
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/30/2024
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/30/2024

Current Sentiment

  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Pyxis Oncology logo
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $3.82
Low: $3.75
High: $3.94

50 Day Range

MA: $3.57
Low: $3.15
High: $3.82

52 Week Range

Now: $3.82
Low: $1.35
High: $6.85

Volume

230,927 shs

Average Volume

628,528 shs

Market Capitalization

$226.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Pyxis Oncology?

The following sell-side analysts have issued reports on Pyxis Oncology in the last year: BTIG Research, HC Wainwright, Jefferies Financial Group Inc., Leerink Partners, Leerink Partnrs, Royal Bank of Canada, Stifel Nicolaus, and William Blair.
View the latest analyst ratings for PYXS.

What is the current price target for Pyxis Oncology?

6 Wall Street analysts have set twelve-month price targets for Pyxis Oncology in the last year. Their average twelve-month price target is $9.00, suggesting a possible upside of 135.6%. Leerink Partners has the highest price target set, predicting PYXS will reach $12.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $7.00 for Pyxis Oncology in the next year.
View the latest price targets for PYXS.

What is the current consensus analyst rating for Pyxis Oncology?

Pyxis Oncology currently has 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PYXS will outperform the market and that investors should add to their positions of Pyxis Oncology.
View the latest ratings for PYXS.

What other companies compete with Pyxis Oncology?

How do I contact Pyxis Oncology's investor relations team?

The company's listed phone number is 617-221-9059 and its investor relations email address is [email protected]. The official website for Pyxis Oncology is www.pyxisoncology.com. Learn More about contacing Pyxis Oncology investor relations.